文献速递消化道肿瘤与早癌

IL22BP介导淋巴毒素对小鼠和人类结直肠肿瘤的抗肿瘤效应

IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans.
PubMed 文献 · Gastroenterology · 2020-06-22

研究探讨IL22BP在结直肠癌发生中的作用。人结直肠肿瘤中IL22BP水平较非肿瘤组织降低,且与淋巴毒素水平相关;小鼠中LTBR信号调控IL22BP表达,LTBR抑制剂在野生型小鼠增加肿瘤负荷但在Il22bp-/-小鼠不增加。IL22BP低表达与结直肠癌患者生存期缩短相关。

要点

  • 人结直肠肿瘤中IL22BP水平较非肿瘤组织降低,且与淋巴毒素水平相关。
  • LTBR信号调控小鼠结肠组织IL22BP表达,LTBR抑制剂在野生型小鼠增加肿瘤负荷,在Il22bp-/-小鼠不增加。
  • 结直肠肿瘤组织中IL22BP水平降低与患者生存期缩短相关。

核心结论

  • 淋巴毒素信号调控结肠中IL22BP的表达;人结直肠肿瘤中IL22BP水平降低,与生存期缩短相关。
  • LTBR信号调控小鼠结肠肿瘤和培养的人树突状细胞中IL22BP的表达。
  • 表达低水平IL22BP的结直肠肿瘤患者可能从IL22拮抗剂治疗中获益。

研究设计与样本

  • 获取结直肠癌患者的肿瘤与非肿瘤组织,用定量聚合酶链反应、流式细胞术和免疫组化检测细胞因子水平。
  • 检测野生型、Tnf-/-、Lta-/-和Ltb-/-小鼠结肠组织中Il22bp信使RNA水平。
  • 给予小鼠氧化偶氮甲烷和葡聚糖硫酸钠诱导结肠炎及相关癌症,或盲肠内注射MC38肿瘤细胞。
  • 部分小鼠给予淋巴毒素β受体(LTBR)抑制剂。
  • 对结直肠癌患者结肠组织芯片(1475个组织芯,含肿瘤与非肿瘤组织)进行免疫组化分析,并将IL22BP水平与患者生存时间进行关联分析。

主要发现

  • 人结直肠肿瘤中IL22BP水平较非肿瘤组织降低,且与淋巴毒素水平相关。
  • LTBR信号为小鼠结肠组织中IL22BP表达所必需。
  • 给予LTBR抑制剂的野生型小鼠在两种模型中肿瘤负荷增加,但LTBR抑制剂未增加Il22bp-/-小鼠的肿瘤生长。
  • 淋巴毒素通过激活核因子κB直接诱导培养的人单核细胞衍生树突状细胞表达IL22BP。
  • 结直肠肿瘤组织中IL22BP水平降低与结直肠癌患者生存时间缩短相关。

临床怎么用

  • 作者认为,表达低水平IL22BP的结直肠肿瘤患者可能从IL22拮抗剂治疗中获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Unregulated activity of interleukin (IL) 22 promotes intestinal tumorigenesis in mice. IL22 binds the antagonist IL22 subunit alpha 2 (IL22RA2, also called IL22BP). We studied whether alterations in IL22BP contribute to colorectal carcinogenesis in humans and mice. METHODS: We obtained tumor and nontumor tissues from patients with colorectal cancer (CRC) and measured levels of cytokines by quantitative polymerase chain reaction, flow cytometry, and immunohistochemistry. We measured levels of Il22bp messenger RNA in colon tissues from wild-type, Tnf-/-, Lta-/-, and Ltb-/- mice. Mice were given azoxymethane and dextran sodium sulfate to induce colitis and associated cancer or intracecal injections of MC38 tumor cells. Some mice were given inhibitors of lymphotoxin beta receptor (LTBR). Intestine tissues were analyzed by single-cell sequencing to identify cell sources of lymphotoxin. We performed immunohistochemistry analysis of colon tissue microarrays from patients with CRC (1475 tissue cores, contained tumor and nontumor tissues) and correlated levels of IL22BP with patient survival times. RESULTS: Levels of IL22BP were decreased in human colorectal tumors, compared with nontumor tissues, and correlated with levels of lymphotoxin. LTBR signaling was required for expression of IL22BP in colon tissues of mice. Wild-type mice given LTBR inhibitors had an increased tumor burden in both models, but LTBR inhibitors did not increase tumor growth in Il22bp-/- mice. Lymphotoxin directly induced expression of IL22BP in cultured human monocyte-derived dendritic cells via activation of nuclear factor κB. Reduced levels of IL22BP in colorectal tumor tissues were associated with shorter survival times of patients with CRC. CONCLUSIONS: Lymphotoxin signaling regulates expression of IL22BP in colon; levels of IL22BP are reduced in human colorectal tumors, associated with shorter survival times. LTBR signaling regulates expression of IL22BP in colon tumors in mice and cultured human dendritic cells. Patients with colorectal tumors that express low levels of IL22BP might benefit from treatment with an IL22 antagonist.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Kempski J, Giannou AD, Riecken K, et al. IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans. Gastroenterology. 2020. PMID: 32585307. doi:10.1053/j.gastro.2020.06.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。